Research on hormone therapy and its effects. Covers menopause symptom relief, bronchiectasis risk, dementia links, and Alzheimer's risk.
Researchers at UCLA found that estrogen therapy's dose, not delivery method, affects risk and benefit for postmenopausal women. Higher doses of conjugated equine estrogen are associated with greater risk of heart disease and certain cancers, especially in obese women.
New narrative review calls for additional research to better understand cardiovascular disease (CVD) and risk factors in transgender individuals receiving long-term cross-sex hormone therapy. Studies suggest worsening cardiovascular risk factors in transgender men and increased thromboembolic risk in transgender women.
A study by St. Jude Children's Research Hospital found that abdominal radiation increases the risk of premature ovarian insufficiency in female cancer survivors, which can lead to infertility and poor overall health. Researchers recommend estrogen replacement therapy to mitigate these risks.
A clinical trial of nearly 2,000 men shows that adding abiraterone acetate to standard therapy for high-risk, advanced prostate cancer lowers the relative risk of death by 37% and increases the 3-year survival rate to 83%. The treatment also reduces the chance of relapse by 70% and serious bone complications by 50%.
The STAMPEDE trial found that adding abiraterone to standard hormone therapy improves prostate cancer survival in men with high-risk disease. The drug reduced disease progression by 70% and severe bone complications by more than half, leading to a 40% increase in overall survival.
Researchers at Northwestern University have created bioprosthetic mouse ovaries using 3D printing, which not only ovulate but also give birth to healthy pups. The study's findings suggest that scaffold architecture plays a crucial role in follicle survival, paving the way for potential human applications.
A new study finds that tamoxifen reduces food intake and prevents fat accumulation, insulin resistance, and fatty liver deposits in female mice fed a high-fat diet. Tamoxifen's protective effects are attributed to the activation of ER°-AF1, opening up possibilities for new therapies.
Women who undergo postmenopausal hormone therapy may be at higher risk of hearing loss, according to a new study. The risk tends to increase with longer duration of use and is associated with older age at natural menopause.
The American College of Physicians recommends treating women with osteoporosis with bisphosphonates or denosumab, while men may also benefit from treatment to reduce vertebral fracture risk. The guideline emphasizes the importance of medication adherence and avoids estrogen therapy due to its associated risks.
A UB-led study of postmenopausal women found that those at the highest genetic risk for fracture benefit most from hormone therapy. The study, which included nearly 10,000 participants, suggests personalized medicine could help prevent fractures in older women.
Researchers demonstrate that an aggressive combination of systemic therapy and local therapy can eliminate all detectable disease in selected patients with metastatic prostate cancer. One-fifth of the patients treated had no detectable disease, with undetectable PSA and normal testosterone levels after 20 months.
A clinical trial found that 13% of patients with high PSA levels after initial hormone therapy showed strong responses to abiraterone acetate, with 5 full responders and partial benefits in 33% of cases.
A Phase 2 clinical trial found that MLE4901 reduced the number and severity of hot flushes by 73% compared to placebo. The treatment was well-tolerated, with no serious adverse events reported. This study demonstrates the potential for MLE4901 as a non-hormonal treatment option for menopausal hot flushes.
A new drug compound targeting brain receptors has been shown to reduce the number of hot flushes in menopausal women by almost three-quarters. The treatment has improved sleep quality and reduced severity of flushing, providing hope for women who cannot take hormone replacement therapy.
A phase 3 trial found that a natural combined estradiol-progesterone capsule significantly decreased moderate to severe hot flashes in postmenopausal women. The treatment was well-tolerated with minimal side effects, presenting an alternative to unregulated hormone therapies.
A study has identified hormones as the cause of inguinal hernias in older men, finding that increased estrogen action and decreased testosterone levels lead to muscle tissue weakness and scarring. The researchers propose using aromatase inhibitors as a potential treatment to prevent recurrence or even surgery.
The study found that E4 lowered testosterone levels in healthy male volunteers, with decreasing total and free testosterone, FSH, and estradiol levels. The hormone was well-tolerated, with only libido decrease and nipple tenderness reported.
A new survey finds that nearly a quarter of transgender individuals in Toronto regard their fertility as important, yet most lack knowledge about reproductive options. Early discussions with healthcare professionals may improve awareness and access to these options.
A new study analyzing over 50,000 patients with prostate cancer reveals a significant link between androgen deprivation therapy and dementia risk, suggesting that long-term use of this therapy may impact brain function. The findings also hint at a possible association between the treatment and Alzheimer's disease.
Scientists are shifting focus to combination therapies targeting multiple appetite control system components, driven by understanding of protein sensors and neurotransmitters. This approach aims to better regulate body's appetite, potentially leading to more effective obesity treatments.
Direct-to-consumer ads for low-testosterone treatments increase prescriptions but may not improve men's health, according to UC Davis physician Richard Kravitz. The rise in hormone-replacement therapies has led to unnecessary treatments and potential cardiovascular risks.
A study found a strong association between TV advertising for testosterone therapies and increased testing, new prescriptions, and treatment initiation. The increase in testosterone use was particularly notable among men without clear indications for treatment.
Daniel J. Drucker, Joel F. Habener, and Jens J. Holst were awarded the Harrington Prize in Medicine for their discovery of incretin hormones and translation into treatments for major metabolic diseases like diabetes. Their work has resulted in breakthrough therapies such as GLP-2 for intestinal disorders.
A survey of military physicians found most lacked formal training on transgender care, had not treated patients with gender dysphoria, and were insufficiently trained to prescribe cross-hormone therapy. The study highlights the need for greater medical training in transgender care among military physicians.
Researchers at University of Alabama at Birmingham discovered endostatin's ability to decrease castration-resistant prostate cell growth in culture. Endostatin reduces oxidative stress and targets hormone receptors, shifting metabolism to scavenge reactive oxygen species.
A recent study suggests that hormone replacement therapy may help improve heart health and overall survival in women, with lower levels of atherosclerosis and plaque buildup detected. The research found significant age-related benefits from the therapy, with women using it being 30% less likely to die than those not on hormone therapy.
A Cedars-Sinai study suggests that hormone replacement therapy is linked with lower levels of plaque buildup in the heart's arteries and improved survival rates among women. Women using HRT were found to be 30% less likely to die than those not on the therapy.
Research suggests that high soy food intake may reduce mortality risk among breast cancer survivors, particularly those with hormone receptor-negative tumors. Isoflavones in soy products have been shown to slow cancer cell growth and possess antioxidant properties.
Researchers at Michigan State University are studying the effect of hormones on ovulation and reproduction in cows to develop better fertility treatments for women. The study aims to improve fertility response rates by understanding how increased doses of fertility hormone impact ovarian function and egg quality.
A new study published in JAMA suggests that testosterone treatments may increase the risk of heart disease in older men. The study found a significant increase in arterial plaque among men aged 65 and older who received testosterone replacement therapy for a year, with a 20% rise in total coronary and noncalcified plaque volumes.
A study published in JAMA and JAMA Internal Medicine found that testosterone treatment improved bone density and anemia, but not cognitive function, in older men with low testosterone. However, it also increased plaque buildup in coronary arteries, raising concerns about cardiac risk.
A new study published in JAMA and J AMA Internal Medicine found that testosterone therapy improved bone density and strength, as well as reduced anemia in older men with low testosterone levels. However, the therapy had no impact on cognitive function and may worsen plaque in coronary arteries.
Researchers found that hormonal maintenance therapy significantly improved survival in women with low-grade serous carcinoma of the ovary/peritoneum. Women who received HMT showed an average progression-free survival of 64.9 months, compared to 26.4 months for those in the surveillance group.
Men treated with testosterone replacement therapy had a 33% lower risk of heart attacks and strokes compared to those who didn't receive hormone therapy. Androgen deficiency is characterized by low testosterone levels, which can cause symptoms like erectile dysfunction and hot flashes.
Research found testosterone treatment improved bone density and anemia for men over 65 with low testosterone, while also increasing plaque buildup in coronary arteries. However, cognitive function remained unchanged.
A large study found that long-term estrogen-based hormone therapy reduced the risk of Alzheimer's disease and improved cognitive function in postmenopausal women. The protective effect may depend on starting hormone therapy at the time of menopause, when neurons are healthy.
A recent study published in Neurology found no association between hormone therapy and the risk of developing Alzheimer's disease. However, women who used hormone therapy for over 10 years showed a reduced risk of Alzheimer's disease compared to non-users.
A new study found that long-term testosterone therapy improves vigor and vitality, while reducing the risk of death due to cardiovascular disease in men with hypogonadism. The research suggests that testosterone therapy is an effective approach for secondary prevention in hypogonadal men with a history of cardiovascular events.
Researchers at King's College London have found that patients with early stages of kidney disease and type 1 diabetes have lower levels of the protective 'anti-ageing' hormone Klotho. This discovery could lead to the development of new treatments to prevent kidney disease in patients with type 1 diabetes.
A nationwide registry of over 1 million patients with hormone-sensitive breast cancer reveals that 1 in 6 women missed post-surgical adjuvant endocrine therapy, which can lower cancer recurrence risk by 29%. Despite improvements, 18% of eligible women remained untreated between 2004 and 2013
A new treatment regimen combining hormonal therapy with radiation treatment significantly improves the average long-term survival of men with recurrent prostate cancer who have had their prostate gland removed. The study found that this regimen also reduces the frequency of spread of the cancer, improving patient outcomes.
Crossing chickpeas is challenging due to self-pollination and inbreeding. Researchers found that emasculation and hormone treatment do not increase cross-pollination rates, instead lowering success rates. Studying environmental factors like light, temperature, and humidity may improve breeding efficiency.
A new study found that a specific type of heart fat associated with an increased risk of coronary artery calcification, an early sign of heart disease. In postmenopausal women and those with lower estrogen levels, epicardial fat volume was linked to higher risk of heart disease.
A study published in The BMJ found that hormone treatment among pregnant women with subclinical hypothyroidism is associated with a lower risk of pregnancy loss, but an increased risk of preterm delivery, gestational diabetes, and pre-eclampsia. Women treated with thyroid hormone had a lower risk of pregnancy loss compared to untreated...
A group of medical experts has issued new clinical guidelines for managing children and adolescents with growth failure, recommending hormonal treatments for certain conditions but cautioning against routine use in cases of unknown cause. The guidelines aim to balance medical needs with potential risks and long-term consequences.
A new study found that most endocrinologists have never received formal training on caring for transgender individuals, despite growing demand for such services. The Endocrine Society is now developing guidelines to address the need for education and training in this area.
A large study of over 9,000 men has established harmonized reference ranges for total testosterone, enabling clinicians to diagnose hypogonadism correctly. The normal range for testosterone in non-obese European and American men between 19-39 years is 264-916 ng/dL.
Women are more susceptible to autoimmune diseases due to a new regulatory mechanism identified by researchers. The study found that the master regulator gene VGLL3 promotes autoimmunity in women, regardless of sex hormone involvement.
A subgroup analysis of the MONALEESA-2 trial found that ribociclib improves progression-free survival in Asian patients with HR-positive advanced breast cancer. The treatment was well-tolerated and demonstrated efficacy regardless of geographic region or self-reported race.
Researchers review newly discovered anticancer molecules and their interactions with DNA, aiming to improve chemotherapy efficiency. New cancer treatment strategies also emerge, targeting tumor cell cycles and promoting apoptosis.
A study of over 5,500 women found that younger patients and those who had taken hormone replacement therapy were less likely to adhere to their medicine. The researchers identified several factors that contributed to non-adherence, including socioeconomic status and marital status, highlighting the need for targeted strategies to impro...
A deficiency of prohormone covertase (PC1) in the brain is linked to most neuro-hormonal abnormalities in Prader-Willi syndrome. The discovery provides insight into molecular mechanisms underlying the syndrome, highlighting a novel target for drug therapy.
A recent study published in Nature Reviews Cancer suggests that progesterone could be a game-changer in treating recurring breast cancers. The hormone, when used in combination with current treatments, may reprogram estrogen action in the breast to improve cancer outcomes. Two new clinical trials are underway to test this approach.
Researchers report good results in patients with metastatic prostate cancer using bipolar androgen therapy (BAT), which alternately floods and starves the body of testosterone. The treatment has been safe and effective, with PSA levels falling, tumors shrinking, and some men showing a complete remission.
Starting testosterone treatment increases risk of serious blood clots, with the risk peaking within six months and declining gradually thereafter. Although the risks are temporary and low in absolute terms, researchers warn that investigating timing and duration of use may have masked conflicting findings.
New York University College of Dentistry has received a grant to investigate potential new compounds for treating osteoporosis. The researchers aim to understand the molecular mechanisms of parathyroid hormone-a related protein and its analogs to develop better-tolerated treatments.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism reveals that menopausal hormone therapy (MHT) improves both bone mass and structure, with benefits persisting for at least two years after treatment ends.
A randomized clinical trial found that both treatment arms met the primary safety endpoint, with improvements reported in vaginal atrophy and sexual interest for all patients. The study also revealed that 37% of patients had elevated estradiol levels at baseline, which could be attributed to estrogen-containing supplements.
Neoadjuvant endocrine therapy is as effective as neoadjuvant chemotherapy for reducing breast tumor size, but with significantly fewer toxic side effects. Aromatase inhibitors were found to be more effective than tamoxifen-like drugs in treating ER-positive breast cancer.
A new study analyzing WHI clinical trials data found that women entering menopause before age 40 have a significantly higher fracture risk. Despite using calcium and vitamin D supplements, the risk remains elevated even with hormone therapy.